StockData
Avalo Therapeutics, Inc. logo

Avalo Therapeutics, Inc. (AVTX) stock

AVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/30
$6.76+0.01 (+0.15%)

Close on Nov 20, 2026Market cap $362.54MP/E –Yield –

Avalo Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Avalo Therapeutics's free cash flow for the twelve months ending Dec 31, 2022 was -$26.85M. For fiscal 2022 it was -$26.85M. The highest annual figure on record is $12.56M in fiscal 2017.

Annual free cash flow

PeriodPeriod endValueChange
FY2022Dec 31, 2022-$26.85M–
FY2021Dec 31, 2021-$71.01M–
FY2020Dec 31, 2020-$40.60M–
FY2019Dec 31, 2019-$19.40M–
FY2018Dec 31, 2018-$3.69M-129.4%
FY2017Dec 31, 2017$12.56M–
FY2016Dec 31, 2016-$14.61M–
FY2015Dec 31, 2015-$10.18M–
FY2014Dec 31, 2014-$15.54M–
FY2013Dec 31, 2013-$11.51M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2022Dec 31, 2022-$3.94M–
Q3 FY2022Sep 30, 2022$5.69M–
Q2 FY2022Jun 30, 2022-$12.53M–
Q1 FY2022Mar 31, 2022-$16.07M–
Q4 FY2021Dec 31, 2021-$17.11M–
Q3 FY2021Sep 30, 2021-$16.37M–
Q2 FY2021Jun 30, 2021-$19.19M–
Q1 FY2021Mar 31, 2021-$18.34M–
Q4 FY2020Dec 31, 2020-$14.38M–
Q3 FY2020Sep 30, 2020-$11.93M–
Q2 FY2020Jun 30, 2020-$8.56M–
Q1 FY2020Mar 31, 2020-$5.74M–
Q4 FY2019Dec 31, 2019-$1.68M–
Q3 FY2019Sep 30, 2019-$7.62M–
Q2 FY2019Jun 30, 2019-$6.81M–
Q1 FY2019Mar 31, 2019-$3.29M–
Q4 FY2018Dec 31, 2018-$2.48M–
Q3 FY2018Sep 30, 2018-$577.48K-103.0%
Q2 FY2018Jun 30, 2018-$340.38K–
Q1 FY2018Mar 31, 2018-$299.65K–
Q4 FY2017Dec 31, 2017-$2.56M–
Q3 FY2017Sep 30, 2017$19.12M–
Q2 FY2017Jun 30, 2017-$1.76M–
Q1 FY2017Mar 31, 2017-$2.24M–
Q4 FY2016Dec 31, 2016-$3.72M–
Q3 FY2016Sep 30, 2016-$3.44M–

More Avalo Therapeutics figures

See a number that looks wrong?